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A growing number of co-crystals in the literature are proof of how signif-
icant the co-crystallization concept has become. Co-crystallization enhances
physicochemical properties through the formation of intermolecular interac-
tions between a drug and a co-former. A co-crystal is a single crystalline material
consisting of at least two molecular components solid at room temperature and
present in a definite stoichiometric ratio. Pharmaceutical co-crystals consist of
the active pharmaceutical ingredient and the co-former selected from generally
regarded as safe (GRAS) list of the United State Food and Drug Administration.
Co-crystal formation requires an understanding of a drug target, a proper choice
of a co-former and is only achieved experimentally after several trials. Other
beneficial co-crystallization outcomes include binary eutectics, solid dispersions,
amorphous forms, etc. Several key issues including design strategies, co-former
selection, and co-crystallizationmethods; tradition and newly syntheticmethods
that are more efficient and suitable for large scale have been briefly described.
The co-crystal preference is demonstrated with a particular emphasis on mul-
tidrug co-crystals and their contribution to the drug combination strategies used
for the treatment and management of drug resistance and adverse side effects in
serious medical conditions that require the administration of high doses such as
HIV/AIDS, tuberculosis, and others.
KEYWORDS
co-crystal development, co-crystallization, design, pharmaceutical co-crystals, preferences,
synergistic co-crystals
1 INTRODUCTION
Less than 1% of active pharmaceutical ingredients (APIs)
reach themarket because of poor biopharmaceutical prop-
erties among which solubility plays a key role.[1] Poor
physicochemical properties of APIs such as chemical sta-
bility, dissolution, hygroscopicity, and solubility impact
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
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therapeutic efficacy.[2] This in turn leads to treatment fail-
ure and development of different side effects, if not mon-
itored. Poor physicochemical properties affect not only
the performance of a drug substance but also impact for-
mulation strategies and other post-formulation processes
such as absorption, distribution, metabolism, and excre-
tion, which may lead to advert effects and toxicity.[3–5]
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Pharmaceutical scientists strive to find a better strategy to
improve properties of the APIs owing to their therapeu-
tic potency, without compromising their chemical iden-
tity. Various methods have been developed and used to
enhance the physical properties of pharmaceutical ingredi-
ents. From a supramolecular perspective, these include the
formation of the amorphous state, polymorphs, hydrates,
salts, solvated forms of drugs, and the formation of phar-
maceutical co-crystals/complexes.[6]
By definition, a co-crystal is a single crystalline mate-
rial consisting of at least two molecular components usu-
ally solid at room temperature and present in a definite
stoichiometric ratio.[7] A broad definition as per Indo-US
meeting 2011, co-crystals are single-phase crystalline solid
materials composed of at least two different molecular
and/or ionic compounds that are neither solvates nor sim-
ple salts and exist in a stoichiometric ratio. Other co-crystal
definitions as per different authors were reported.[8]
According to different literature, co-crystal formation
enables the modification of fundamental physicochemi-
cal properties of pharmaceuticals such as solubility, stabil-
ity towards thermal and humidity stress, dissolution rate,
and compressibility.[9–23] Henceforth, the co-crystal for-
mation of drug substances offers a great opportunity to
develop drug products with better physicochemical prop-
erties without changing the pharmacological properties of
the API. Due to this, there has been a very intense desire to
design co-crystals for different applications which eventu-
ally make co-crystallization a preferred technique in phar-
maceutical sciences.[24,25] Other physical properties such
as hygroscopicity, stability, crystallinity, particle size, flow,
filterability, density, and taste, which may be changed as
well, preferably improved by co-crystallization leading to a
better therapeutic effect.[26] Interestingly, even though the
first co-crystal structure was solved by FriedrichWohler in




Based on the definition given above, a co-crystal is a multi-
component molecular complex non-covalently bonded,
in which one molecule is neutral and the second com-
ponent is termed the co-former. A “pharmaceutical co-
crystal” is made of an active pharmaceutical ingredient
(API) and a co-former. This is either anionic or a neu-
trally safe inactive chemical selected from the Generally
Regarded as Safe substance (GRAS) list mostly provided by
the United States Food and Drug Association list (FDA) or
it could be another API.[27,28] Both co-crystal components
are solid at ambient temperature and present in known sto-
ichiometric amounts.[29] Co-crystallization of theAPIwith
pharmaceutically acceptable co-crystal formers has gained
increasing attention due to the abilities of this approach to
achieve a complex without altering the chemical structure
or nature of both drug components.[30]
1.2 Co-crystal properties
Properties of a co-crystal depend mostly on the selected
co-former[31,32] and the types of intermolecular interac-
tions formed during the co-crystallization process. This is
one of the advantages of co-crystal synthesis over other
techniques used to improve the physicochemical proper-
ties of the drug substance[32] among which salt formation,
micronization, and amorphization are found.
Pharmaceutical co-crystal formation involves APIs
forming non-covalent bonds with co-formers or other
APIs. The presence of either hydrogen donor or acceptor
groups on molecules forming a co-crystal is fundamental
because the best donor generally associates with the best
acceptor in the crystal structure.[33,34]
The hydrogen donors or acceptors are functional groups
such as amide, primary and secondary amine, carboxylic
acid, hydroxyl groups, thioester, thiazole, and others. Dif-
ferent properties of a co-crystal such as melting point,
physical, and chemical stability, solution stability and crys-
tallinity, dissolution, and bioavailability, have been thor-
oughly discussed in the literature.[6,8,35]
2 CO-FORMER SELECTION AND
CO-CRYSTAL DESIGN
The selection of a co-crystal former compatible with an
API is a crucial step in the co-crystal design but also one of
the challenges faced during the co-crystal formation pro-
cess. The general strategy used in co-former selection is
by trial and error also known as a tactless approach dur-
ingwhere a number of the pre-determined pharmaceutical
library of acceptable compounds (drugs found in General
Regarded as Safe (GRAS) FDA list of drugs) are used in the
co-crystallization attempt.
A co-crystal is considered strategically on the follow-
ing basis: when a co-former has a complementary func-
tional group(s) that can join to the drug candidate through
supramolecular synthons by the means of intermolecular
interactions.[31] Properties (mainly physical and chemical)
of the produced co-crystal depend on the co-crystal for-
mer used. This makes the selection of co-crystal former a
paramount step in the co-crystal synthesis process. When
the co-crystal former is selected from the US-FDA GRAS
list any drug excipient, neutral, acid, or base, safe according
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to this list can be considered. Further, pharmaceutically
accepted salts are also used as co-formers[8] and result in
multicomponent salts or co-crystal salts where there is a
partial transfer of proton and formation of intermolecular
interactions at the same time.
A co-crystal former may also be another active pharma-
ceutical ingredient (API). However, the selection of such
substances should fulfill certain criteria, with the inten-
tion to improve properties and biological activity of either
or both active(s) in the co-crystal system. APIs with poly-
morphic properties have been used as co-crystal formers.
Such combinations offer better stability to the system com-
ponents. This is one of the techniques used to prevent
unwanted polymorphs which most of the time come with
serious effects in terms of drug performances.[36] Com-
pounds which crystallize with more than one molecule
in the crystallographic asymmetric unit (Z 0 > 1) have
also been suggested as good co-crystal formers.[36] Amor-
phous compounds are another class of drugs that have
been proven relevant as co-crystal formers due to their
enhanced solubility profiles.[37]
Despite their poor bioavailability, nutraceuticals which
by definition refer to food or part of food that provides
medical or health benefits and an ability to prevent and
be used as a treatment of a disease can also be used
as co-formers.[38,39] Therapeutic effects associated to
these drugs is a target for solid-state chemists and when
co-crystallized with APIs would enhance physicochemical
properties, stability, solubility as well as bioavailability of
drug product (co-crystal or hybrid) and generate priceless
and cost-effective synergistic hybrids, being affordable,
and easily attainable.[40] This also reflects their structures
offering robust supramolecular synthons.[41] This sub-
stantial degree of freedom to select co-formers and the
subsequent diversity of the co-crystals, have made the
co-crystallization very attractive as a method to fine-tune
properties of APIs.
A few examples of such drugs that have been previ-
ously used in co-crystal formation have been reported.[41]
In addition to the synergistic effects of nutraceutical-API
combinations, these drugs may also play a crucial role in
interconnecting APIs in a multi-drug crystal lattice. The
use of nutraceuticals has been reported; flavonoids and
vitamins are examples of nutraceuticals investigated and
used as co-crystal drug candidates to enhance physico-
chemical properties and bioavailability.[42] Systematically,
the choice of co-former is usually based on a supramolec-
ular approach.[23]
According to Duggirala et al. property optimization of
drug substances was the main goal of crystal engineer-
ing scientists in the co-crystal design.[44] Authors estab-
lished that the design and synthesis of co-crystals rely
exclusively on the presence of supramolecular synthons. It
F IGURE 1 Supramolecular synthons and their occurrence per-
centages based on the Cambridge Structure Database (CSD). On the
left are common homosynthons; acid-acid or carboxylic acid dimer
and amide-amide homosynthon or carboxamide dimer. On the right
are regular heterosynthons; carboxylic acid-pyridine, carboxylic acid-
carboxamide, and carboxamide-pyridine heterosynthon[43]
has been demonstrated that co-crystals with strong hydro-
gen interactions are designed based on the supramolec-
ular synthons approach. These supramolecular synthons
are referred to as structural units within supermolecules
that can be formed and/or assembled by knownor conceiv-
able synthetic operations involving intermolecular interac-
tions. In a crystal system, supramolecular synthons are the
smallest structural units within which is encoded all infor-
mation inherent in the mutual recognition of molecules to
yield that crystal (or solid-state supermolecules).[45,46]
Just like the known reactants to make specific covalent
bonds, the choice of a synthon which is likely to form
during a crystallization process is crucial. Examples of
such synthons are depicted in Figure 1. A crystal struc-
ture is simplified as a network in which molecules are
seen as nodes and molecule synthons seen as connectors
of those molecules.[45,47,48] In most cases, hydrogen bonds
(H-bonds) due to their strength and directionality com-
pared to other intermolecular forces are involved in syn-
thons. However, this doesn’t withstand the contribution of
various other intermolecular forces such as halogen bonds,
π−π interactions in aromatic structures, stacking interac-
tions and van der Vaal interactions as these contribute to
the final results of crystallization [32] aswell as a significant
role in the co-crystal formation.[34]
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A very good understanding of synthons is also
paramount for a better selection of co-crystal formers. The
co-crystal design also requires a good understanding of the
intermolecular interactions. Intermolecular interactions
are the fundamental key of supramolecular chemistry. He
also described these weak interactions as what keeps the
organic world together.[49,50]
Interactions such as hydrogen bonding; strong (2.2–
2.5Å), intermediate (2.5–3.2Å) and weak (3.2–4.0 Å) with
angle cutoffs > 90 degree,[51] π−π stacking (either in a
flat configuration with face-to-face arrangement or edge
configuration with edge-to-face arrangements),[52–54] elec-
trostatic, hydrophobic, charge transfer, metal coordina-
tion, halogen bonding, and metallophilic interactions [55]
interconnect molecules in the lattice via different
supramolecular synthons discussed in the previous
paragraphs. Molecular recognition (which is a neces-
sary complementarity between molecules forming an
aggregate) is compulsory in this formation and stabiliza-
tion of supramolecular systems. In such entities, these
interactions are like bridges between molecular building
blocks.[56]
Among these interactions, H-bond is predominant and
most explored mainly due to its directionality, its natural
existence (ubiquitous), from just a drop of water, DNA
to large supramolecular assemblies.[57] According to the
IUPAC Recommendations 2011, H-bonds are attractive
interaction between a hydrogen atom from a molecule or
molecular fragment X–H in which X is more electroneg-
ative than H, and an atom or a group of atoms in the
same or a different molecule, in which there is evidence
of bond formation.[58] The commonly known strong
hydrogen bonding in solid materials such as co-crystals
is O–H⋅⋅⋅O, N–H⋅⋅⋅O or O–H⋅⋅⋅N; Figure 2 illustrates this
type of interactions. The weak hydrogen bonding include
C–H⋅⋅⋅O, C–H⋅⋅⋅N and N–H⋅⋅⋅π.
Attraction dispersive and (or) inductive forces between
molecules promote the formation of interaction known as
“Van derWaals”. These forces are responsible for the for-
mation of solid dispersions.
Molecules containing halogens such as Fluor tends
to form halogen bonding interactions during the self-
assembling process. According to Desiraju et al. “halogen
bond” occurs when there is evidence of a net attractive
interaction between an electrophilic region associatedwith
a halogen atom in a molecular entity and a nucleophilic
region in another, or the same, molecular entity.[60] The
halogen bond is also characterized by its directionality,
strength, polarity, hygroscopicity, donor-atom dimension,
and its tenability.[61]
Other intermolecular interactions include C–H—π
weak bond that plays an additional or secondary role in
molecular recognition, therefore reinforcing interactions
F IGURE 2 Example of O–H. . .O H-bonding between
acetaminophen and oxalic acid space group P21/c shown alongside
b-axis. (Mercury)[59]
such as hydrophobic effects. An example of how important
this kind of interaction is seen in the non-polar hydrocar-
bon encapsulation.[62] The type of hydrogen bonding and
other interactions between molecules in the co-crystal is
determined by the type of supramolecular synthons avail-
able.
Furthermore, an API with abundant hydrogen bonding
sites and molecular flexibility may be manipulated by a
proper choice of solvent to form a specific form of crystal
possessing a different arrangement and conformation
to the original crystal lattice.[63] In fact, the change of
molecule arrangement in the crystal lattice leads to mod-
ified solid-state properties affecting its solubility, disso-
lution, stability, and ultimately bioavailability. Therefore,
different crystal forms can lead to changed biological
activity (lower or higher than desired).[42] For co-crystals
produced by solution crystallization methods, two com-
ponents must have similar solubility in a chosen solvent;
otherwise, it is unlikely to produce a co-crystal. This
is because the difference in solubility will lead to the
precipitation of the least soluble part, leaving the other
component in the solution.[57]
3 CO-CRYSTAL CLASSIFICATION
Even though co-crystals classification should primarily
depend on the useful nature of component drugs, scien-
tists and researchers approach this issue by overseeing the
content of the structure rather than their utility. This is
due to the diversity of co-crystals and their wide range
of uses which include but not limited to medicinal or
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pharmaceuticals, mineral, agrochemistry, engineering,
crystallography, and energy.[64,65]
Based on factors such as the number of component
molecules in the crystal structure and presence in the
structure of an ion, polymorph, water, or solvent, one can
divide co-crystals in two main classes:
Class 1 includes “binary co-crystals”; the two compo-
nents single solid crystalline substances designed based
on hydrogen bonding propensity, supramolecular syn-
thons, Hansen solubility parameters, pKa values.[66] Typ-
ical examples of this type are pharmaceutical co-crystals
where one structural component is an active pharmaceuti-
cal ingredient and the second being a co-former selected
from the United States Food and Drug Administration
(US-FDA) list of generally regarded as safe (GRAS) drugs.
Binary co-crystals class is further divided in two groups
depending on whether molecules in the crystal lattice are
hydrogen or halogen-bonded.[57]
“Ternary and quaternary co-crystals” respectively
composed of three and four neutral drugs arranged in a
definite stoichiometry in their crystal structures. Using
isoniazid and nicotinamide, Aitipamula et al. produced
two tertiary co-crystals using fumaric and succinic acid.[67]
In both cases, hydrogen bonding occurs via pyridine-acid
synthons.[29,66] Synthesis of such multicomponent solids
provides an opportunity to explore the combination of
drugs usually administered separately, targeting different
sites or drugs with synergistic effects. Other examples of
this type were reported previously.[68]
The second class of co-crystals includes Polymorphic
co-crystals: Investigation on different polymorphic
forms of a particular compound is common in solid-state
pharmaceuticals. Polymorphism is common in solid-
state chemistry. Investigating polymorphism is crucial
during drug development because polymorphic forms
exhibit different physical and chemical properties. The
future or safety post-manufacturing of a drug formulation
depends on how well this step was explored. Like any
other chemical entity, identifying all possible forms during
the development of the co-crystals is paramount.
Even though co-crystallization has been attributed to
reducing polymorphism propensity,[25,42] polymorphic co-
crystals have been reported.[69] Different polymorphic
co-crystals of the same drug exhibit different physico-
chemical properties.[70] Polymorphism in co-crystals is
promoted by different factors, among which co-crystallize
drugs belonging to families with polymorphism history
or use of polymorphic co-formers[71] being the primary.
Compounds that exhibit polymorphism also enable the
formation of heteromeric intermolecular interaction with
co-former molecules (target molecules) over monomeric
interactions and allow the existence of different molecules
in the same crystal lattice, theoretically making them pos-
sible good co-crystallizing agents.[29] However, only prac-
tically this can be proven.
It is therefore important to investigate these aspects
with vigilance as the outcomes may be catastrophic for a
pharmaceutical company if unwanted polymorph is for-
mulated. An example of co-crystal polymorphism was
observed when a chloroform solution of caffeine and glu-
taric acid were allowed to evaporate slowly and two poly-
morphs having different morphologies rods (form I) and
blocks (Form II) were produced.[10]
Salt co-crystals: Before the introduction of co-crystals,
the salt formation was among approaches used to modify
the physical properties of APIs. This is evidenced by statis-
tics approximating that over half of the medicines on the
market are administered in salt forms.[8] Salt formation
suffers from the limitation that only compounds/APIswith
ionizable site fit to be processed.
Formation of co-crystals involving ionic substances
was introduced after the discovery of polymorphic
forms (a neutral and zwitterion forms) of piroxicam/4-
hydroxybenzoic acid co-crystal (1:1, v/v). Different
salt-co-crystals also known as ionic co-crystals have been
reported. A dozen of salt/ionic co-crystals were previously
synthesized in our lab using bis(1-adamantylaminium)
carbonate with neutral mono and dicarboxylic acids as
co-crystal formers.[35]
Solvated/hydrated co-crystals constitute another
type of co-crystals in which solvent/water molecules
are part of the crystal structure. In some cases, these
guest molecules are what keeps a crystal together, and
collapse upon desolvation or solvent/water molecule




Co-crystallization doesn’t always produce co-crystals, solid
forms such as eutectic mixtures, salts, solvated, ionic
liquid, solid dispersions, solid solutions, supramolecular
gelators can sometimes result from the co-crystallization
process.[74] Factors such as the nature of the components,
environment (solvents, temperature, pH) contribute to the
occurrence of these adducts.[43]
Hydrate/solvate formation commonly occurs when
water/solvent molecules are incorporated into the crys-
tal lattice.[75] The presence of this may significantly
contribute to molecular networks within a crystal and
sometimes these entrapped solvent molecules are what
hold the crystal molecules together (this is the case of
polymorphic solvates when solvent molecules are an inte-
gral part of the crystal structure) and the crystal collapses
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F IGURE 3 Different co-crystallization
solid forms based on discussion by
Cherukuvada et al[79]
upon desolvation which eventually results in a disordered
system known as solid amorphous form.[76] Alternatively,
the solvent molecules fill the voids in the crystal and can
be easily removed by desolvation without affecting the
crystal structure. This is the case of pseudopolymorphic
solvates.[77] A particular example is that of caffeine where
hydration maintains the order in its both polymorphic
crystals. Before co-crystallization with water, molecules
in both polymorphs lack orders.[43] The Cambridge Struc-
tural Database (CSD) indicates the solvation ubiquity of
43% among organic crystals reported.[59]
It happens often that instead of a co-crystal, drugs (i.e.,
APIs) combined via co-crystallization result in what is
known as eutectic mixtures (EM) [78] or solid dispersions.
Eutectic Mixtures (EM) are multicomponent solids that
are recently gaining much interest of researchers in the
pharmaceutical field. EMs are obtained as a result of the
failed co-crystal formation. Due to an increased number of
researches in pharmaceutical co-crystals, pharmaceutical
eutectics are likely to increase even more.[74]
Based on the definition according to Cherukuvada and
Nangia,EMs are conglomerates of solid solutions inwhich
similar molecules are held together by strong cohesive
interactions whereas unlike ones are bound by weak adhe-
sive forces. However, this class of multicomponent solids
lacks a distinct crystal structure despite the above inter-
actions binding their molecules together. Instead, their
crystalline nature resembles that of parent compound
combinations (this can be easily justified by the similari-
ties between diffraction patterns). Furthermore, eutectics
are thermally characterized by lower melting points than
that of their drug components intact and they present
themselves as important in enhancing the physicochem-
ical properties of the drug components (API(s) in case
dual drug) as their co-crystals counterparts.[79] Other solid
forms which may be resulted from co-crystallization but
which won’t be discussed here include those summarized
in Figure 3.
5 THE CO-CRYSTAL DEVELOPMENT
PATHWAY
The development pathway of pharmaceutical co-crystals
has been encompassed into eight stages.[44] These include:
Co-former identification : Initially, a complementary
co-former to a drug molecule candidate is selected from a
library (depending on the type of co-crystal to be synthe-
sized). In the case of pharmaceutical co-crystals, the co-
former is selected froma generally regarded as safe (GRAS)
list provided by the FDA and Everything Added to Food in
the United States (EAFUD) list approved by the FDA.[80,81]
Discovery : A stage during which co-crystal synthesis
is carried out. Methods such as slow solvent evaporation,
slurry mediated transformation and mechanical grinding
(both neat and solvent-drop or liquid assisted) are used.
Other methods used during co-crystal screening are also
identified.[44]
Characterization : A stage during which physical and
chemical properties are assessed is carried out using differ-
ent techniques. Differential scanning calorimetry (DSC),
thermogravimetric analysis (TGA), infrared and Raman
spectroscopy, powder X-ray diffraction (PXRD), single-
crystal X-ray diffraction (SCXRD), and solid-state nuclear
magnetic resonance (ss-NMR), are used to characterize
novel co-crystals.[82,83]
Properties : This was described as a stage during which
further steps would be decided. In case the produced co-
crystal shows enhance desired properties such as aqueous
solubility and dissolution rates, pharmacokinetics, formu-
lation, reproduction, and scale-up will be performed. Co-
crystallization also enables the improvement of properties
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such as physical and chemical stability as well as manufac-
turability.
Evaluation of pharmacokinetics : Evaluating pharma-
cokinetics (Pk) of a drug is a crucial step in drug develop-
ment. The drug performance and drug-action site flow are
explored during this stage. It is based on this route of drug
administration, and the dose for any medication is deter-
mined. Pk is often defined as a study of processes such
as drug absorption, distribution, metabolism, and elimina-
tion of a patient’s body. Changes in physicochemical prop-
erties which supramolecular systems such as co-crystals
deliver result from changes in thermodynamics of APIs.
These, in turn, affect not only drug bioavailability but also
the Pk of a drug through processes outlined in the previ-
ous paragraph (timely exploring but not limited to the drug
quantity (concentration) in biological fluids, tissues, and
excreta.[84]
Different studies witnessed improved pharmacokinet-
ics of APIs by co-crystallization. Of these, the study by
Dooner et al. reported increased pharmacokinetics of both
APIs in Tramadol-Celecoxib co-crystal.[85] Other examples
include those highlighted by Duggirala et al.[44] Therefore,
evaluating the Pk of a new drug substance and new deliv-
ery systems such as co-crystal is an important step in the
development process of a drug.
Formulation : The formulation of a co-crystal in a
dosage form is not a straight forward process. Held
together by hydrogen bonds co-crystals stability in the
presence of excipients that also contain hydrogen bonding
groups becomes a major concern and presents a great risk.
Choosing the right excipients is paramount to minimize
the possible source of interactions with the co-crystal.[44]
The stability of co-crystals into formulation is of major
concern. This is because co-crystals are stabilized by H-
bonds and the risks associated with the use of excipi-
ents already containing H-bonds are high, especially those
excipients designed to enhancing properties of a drug in
the formulation.
Further, pharmaceutical co-crystals, having enhanced
physicochemical properties, behave differently from their
pure API. Regardless of their H-bonds-dependent stability,
require an adjustment and manipulation of the excipients,
amount of API required to produce the same activity, and
change of the formulation method where necessary.[44,86]
Additionally, more studies are needed to address issues
encountered during pharmaceutical co-crystals formula-
tion. The use of examples to explore the implication of
co-crystal in the formulation stage doesn’t draw a steady
conclusion. Nonetheless, different examples have been
used to explore risks associated with the formulation of
pharmaceutical co-crystals.[44]
Process and scale-up : Scale-up of the co-crystal pro-
duced by traditional solutionmethods of co-crystallization
such as solvent evaporation and slurry) present challenges.
Good quality co-crystals are obtained from solution crys-
tallization, a method usually used to purify chemical sub-
stances such as APIs. Not only the problem of solvent cost
and solubility of the individual component but also the
tendency to crystallize which is different for these com-
ponents reduce the chances of reproducing the same co-
crystals with the desired yields.[87]
For many co-crystals prepared using simple and com-
mon solid-state approaches known as mechanochemi-
cal approaches, there are challenges with required high
mechanical stress and the difficulty in achieving a homo-
geneous final product for larger-scale processes. Nonethe-
less, alternative methods such as extrusion (twin-screw)
and resonant acoustic mixing can help prepare large vol-
umes and only require the addition of small amounts of
solvent during the process.[44,88,89]
Finally, there is regulatory approval and patenting stage
during which a co-crystal undergoes different evaluations
for patenting purposes. Initially, intellectual property pro-
tection must be ensured. Pharmaceutical co-crystals fulfil
three primary criteria for issuing a patent. These are a nov-
elty, non-obviousness, and utility (the drug substance has
pharmacological activity and/or improved performance vs.
the corresponding single component drug substance) and
so can be patented.[44,90]
6 CO-CRYSTALLIZATIONMETHODS
There is a wide range of different methods used success-
fully for co-crystal preparation. Some of these have been
used for decadeswhile otherswere recently introduced fol-
lowing the intensive growth in co-crystal applications and
commercialization. Old as well as new co-crystallization
methods have been extensively reviewed.[64]
Conventional methods such as solvent evaporation,
slow cooling evaporation, vapor diffusion can be grouped
into solution crystallization, whereas other methods
include grinding (either solid-state, or liquid-assisted),
slurry conversion, melt crystallization, hot-melt extrusion,
and spray crystallization. With new advances in technol-
ogy, different methods are now available and summarized
in five classes: solid-state, solution-based, supercritical
fluid, and miscellaneous co-crystal preparation.[64]
6.1 Solid-state co-crystal preparation
Solid-state methods use different mixing exercises and
manipulation of the target drug and the co-former in their
powder or crystalline form to produce co-crystals. Partial
wetting of the samples may be required for some of these
methods.[64,91]
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6.1.1 Contact formation of the co-crystal
This is a spontaneous formation of the co-crystal upon
gently mixing the API and co-former without any physi-
cal application of force. Such spontaneity requires changes
in free energy evaluated from solubility and equilibrium
constants.[92] Various examples have been given. Results
obtained did not all agree with thermodynamics of the
samples, it was then indicated that the co-crystallization
rate can also be affected by other factors such as diffusiv-
ities, molecular mobility, molecular interactions and sur-
face interactions [92] in addition to high temperature and
relative humidity.[64]
6.1.2 Solid-state grinding methods of
co-crystal preparation
The most popular solid-state methods; dry (neat) grind-
ing (DG) and liquid-assisted grinding (LAG) have been
widely used in co-crystal preparation. Both DG and LAG
are what constitute solid-state grinding also known as
mechanochemistry; a method developed as an alternative
to solution-based methods of co-crystal preparation. This
method is simple, green, reproductive, clean, reliable and
yield is imminent which is advantageous over solution-
based methods.[93,94]
Dry grinding (DG) uses pressure generated manually
(using a mortar and pestle) or by mechanical forces cre-
ated by an automated ball mill to combine the target drug
and the co-former. Usually, sample preparation using this
technique is carried out at room temperature and where
an automated ball mill is used, the temperature must be
monitored and recorded to address any changes if any and
reported. Despite its effectiveness, simplicity, and other
advantages, DG is associated with failure or incomplete
conversion to co-crystal and possible generation of unsta-
ble amorphous as a result of crystal defect.[64,95,96]
Liquid-assisted grinding (LAG) refers to grinding
assisted by the addition of a very small amount of solvent to
the mixture at the beginning and during the grinding pro-
cess. The solvent places a catalytic role, therefore acceler-
ates and promote the formation of the co-crystal. Different
co-crystals have been produced using LAG.[64,96]
6.1.3 Extrusion
Extrusion is a relatively new method that uses a twin-
screw extruder to simultaneously mix and pressing the
startingmaterial or amixture of startingmaterials through
a die under a controlled environment. Unlike Hot melt
extrusion which involves melting the samples and mix-
ing at high temperature,[97,98] here, the process is main-
F IGURE 4 Lattice of the co-crystal between carbamazepine
and para-aminosalicylic acid, view alongside b-axis, with no hanging
contacts and molecules; Mercury[59]
tained below the melting temperature of either content of
the sample being processed.[99] Different co-crystals were




The co-crystal preparation from solution requires super-
saturation of the target drug and co-former; followed by
the nucleation process, then the crystal growth. Good care
and conditions must be established to ensure the thermo-
dynamic stability of the co-crystalline suspension (sample
containing solution).
Apart from the conventional methods outlined at
the beginning of this section, solvent-mediated and
precipitation can also be used to produce co-crystals.
Further, the majority of co-crystals reported in the Cam-
bridge structural database were produced by solution
co-crystallization.[64,100] A particular example is that
of carbamazepine (CBZ); an anticonvulsant with para-
aminosalicylic acid (PASA) an antitubercular (Figure 4).
6.2.1 Evaporative method of
co-crystallization
Evaporative co-crystallization (ECC) has been widely used
to produce co-crystals. The super-saturation is achieved
as solvent volume reduces upon evaporation, which in
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turn increases the concentration of co-crystalline mix-
tures in the solution. ECC is an effective and preferred
method to produce good quality single crystals fit for single
X-rays diffraction. Atmospheric conditions (temperature
and pressure) must remain constant throughout the exper-
iment to ensure reproductivity, reliability of the co-crystal
product and consistency between batches.[64,101]
The high evaporation rate leads to accelerated co-
crystallization. However, this was associated with the
formation of unstable/metastable crystals. Consequently,
slow evaporation of the solvent is recommended.
6.2.2 Cooling crystallization (CC)
Cooling crystallization is another solution method of co-
crystal preparation. Supersaturation required for co-crystal
growth is achieved by cooling the co-crystalline solution.
A drop-in temperature decreases the solubility of both co-
formers, leading to precipitation tendency and subsequent
co-crystal growth. Among co-crystals produced via CC are
co-crystals of carbamazepine/nicotinamide obtained from
ethanol.
6.3 Supercritical fluid methods
Supercritical fluid technology has been successfully used




During the use of this technique, theAPI and the co-former
are suspended as a slurry in liquid or supercritical CO2,
using the solvent power of supercritical CO2 and not that
of toxic organic solvents. First, thermodynamic of CO2 is
controlled to fine-tune its density as well as solvent power.
This, in turn, allows the control over co-crystallization
between components of the co-crystal.[64]
The application of this technique was shown an
increased rate of co-crystallization. This is due to an
intense mass transfer by convection which is promoted by
stirring co-crystal components in CO2 slurry, which in turn
offer a complete co-crystallization and results in a highly
pure co-crystal.[64]
6.3.2 Rapid Expansion of Supercritical
Solvents (RESS)
This method consists of saturation of the supercritical
fluid (supercritical CO2 with an API and co-former
before the depressurization of the CO2 phase through
a nozzle into a drying chamber at atmospheric pres-
sure. Unfortunately, this method requires that API
and co-former be solubility in supercritical CO2 while




This method uses supercritical CO2 as an antisolvent for
the co-crystallization process. On contrary to RESS, this
method requires that API and the co-crystal former have
reduced solubility in supercritical CO2 to allow precipita-
tion of two as one co-crystal structure. Once in a vessel, the
CO2 dissolves in the used solvent leading to simultaneous
volume expansion, reducing the solubility of that solvent,
therefore resulting in precipitation.
Using its two techniques, such as batch gas anti-
solvent (BGAS) during which the solution contained
both API and co-crystal former, is saturated with CO2
in a high-pressure vessel until co-crystallization takes
place. The second technique is a semi-continuous
supercritical antisolvent (SSAS) process during
which an API-co-former solution is forced through




Among the miscellaneous method of co-crystal prepara-
tion, there is the use of high-power CO2 laser to irradiate
powder blends of co-crystal formers, which then promote
recrystallization to a co-crystal. This method is known
as “laser irradiation”. It is assumed that the rearrange-
ment of co-formers molecules, as well as nucleation, occur
in a vapor phase. This is because it was seen that co-
crystallization can only take place if co-crystal formers sub-
limate enough.[64]
6.5 Freeze-drying
Also known as lyophilization has been wildly used
in preserving a variety of products including pharma-
ceuticals. The material solution is frozen at a con-
trolled (reduced) surrounding pressure to allow the frozen
water in the material to sublime. This method has
potentially been used to prepare solid-state co-crystal
forms.[102]
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6.6 Electrochemically induced
Co-crystallization
Electrochemically induced Co-crystallization is another
miscellaneous method that uses electrochemistry to incite
co-crystallization by creating a conducive environment for
the process (pH adjustment to neutral and generate neces-
sary local forces).
6.7 Resonant acoustic mixing
Co-crystal preparation relies on the acoustical transfer of
mechanical energy to a wetted powder mixture (drug-
co-former). This form of energy transfer encourages the
intimate mixing of the components, therefore increasing
chances for co-crystal formation.[103,104]
6.8 Spray drying
Spray drying is a well-known method used to produce dry
powder from solutions, emulsions and suspensions. The
advanced technology which allows a highly-controlled
environment and use of hot steam air to rapid evap-
oration of the used solvent, the method is very fast
and produce pure co-crystals when compared to other
solution co-crystallization methods. For this reason,
spray drying is among the most preferred method for
the preparation and scale-up.[105] The method has been
widely used in the production of amorphous solid dis-
persions, this method can also and has used to prepared
co-crystal.[64,106]
6.9 Electrospray technology
This method leads to liquid atomization using electrical
forces where the liquid flows out a capillary nozzle at
high electric potential, and then the liquid is forced by the
electric field into a dispersion of fine and highly charged
droplets. After drying, the resulted particles are collected
using a charged powder collector. All these methods have
been thoroughly discussed with examples.[64]
7 PREFERENCE OF
CO-CRYSTALLIZATION
The scientific need for using the co-crystallization process
as a potential tool to enhance the desired properties of
drug substances has recently increased significantly due to
the benefit of this approach over a variety of other tech-
niques outlined at the beginning of this chapter. Further,
the uniqueness with respect to the structure and proper-
ties, of each product of co-crystallization (novelty), a vari-
ety of solid forms (Figure 3) that can be resulted from
this approach (non-obviousness), each of them exhibit-
ing unique physicochemical properties (utility) based on
which different application may be evaluated. Simplicity
and the greenness of co-crystallization confer makes this a
remarkable method.[43]
Additionally, co-crystallization around an API increases
the protection of its intellectual property (IP), by reducing
the risks and industrial crisis in case the drug loses its effec-
tiveness over time while on market (reducing the risk of
costly litigation and market erosion).[107]
Co-crystallization also stabilizes drugs known to exhibit
polymorphism issues.[108] The latter being the ability
of a substance to present itself in different crystalline
forms (also known as polymorphs) characterized by
the same chemical composition (same substance) but
different physicochemical properties, structure arrange-
ments (molecules are joined and arranged differently in
lattices).[6]
It is mandatory to know that the formation of hydrogen
bonds during the co-crystal screening is dependent on the
molecular complementarity of the co-crystal formers and
plays an important role in structure directions due to the
molecular flexibility they offer. It is from this supramolec-
ular concept where the idea of drug-drug co-crystallization
comes. This concept of drug-drug co-crystallization will be
discussed in subsequent sections.[109,110]
Assisted by the Cambridge structure database crystal
engineering helps the understanding of intermolecular
forces involved in hydrogen bonding between molecules
(organic mostly). The presence of functional groups that
engage in hydrogen bond formation makes the molecular
nature of drugs a key factor in the co-crystallization pro-




Multiple drugs combination in a single dosage form for
oral administration has become a popular drug develop-
ment strategy mainly due to its abilities to boost the treat-
ment effect and improvement of diseasemanagement. The
advantage gained from this is also reflected in patient
adherence and reduction of product development costs.
Such benefits and much more can also be obtained from
combined drugs in the pharmaceutical co-crystals.[111]
Despite their potential as recognized by different solid-
state scientists, not much attention has been given to
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them, only a little is found in the literature. However, with
the present increase of complex medical conditions and
increased pressure in the discovery of new APIs, these
hybrids are of utmost importance.
Drug-drug or multidrug co-crystallization is the rela-
tively unexplored technique for the design of solid APIs,
and according to the literature, the use of this technique
may produce co-crystals with potential applications in
terms of drugs combination and improved properties for
further development.[41] Hence, for Bhupinder, the idea of
developing a multiple-drug co-crystal is reflected in recent
publications and patent applications.[36,112–115]
According to Thipparaboina et al. multidrug co-crystals
are dissociable solid crystalline supramolecular complexes
comprising two or more therapeutically effective compo-
nents in a stoichiometric ratio within the same crystal lat-
tice, wherein the components may predominantly interact
via non-ionic interactions and rarely through hybrid inter-
actions (a combination of ionic and non-ionic interactions
involving partial proton transfer and hydrogen bonding)
with orwithout the presence of solvatemolecules. This def-
initionwas reconstructed based on FDAguidelines accord-
ing to which co-crystals are dissociable multi-component
solid crystalline supramolecular complexes composed of
two or more components within the same crystal lattice
wherein the components are in a neutral state and inter-
act via non-ionic interactions.[116]
The multidrug co-crystals implement the patent eligi-
bility criteria such as non-obviousness, novelty, and util-
ity for pharmaceutical development.[117,118] According to
Ghadi et al. there was no record of multidrug co-crystals in
the literature. However, this statement was later changed
and now, due to an increased interest of researchers on
these adducts, the number of reports is evolving in the
literature.[41]
A more explicit definition of multidrug co-crystals takes
into consideration the growing literature on salt/co-crystal
hybrids and ionic co-crystals thus includes hybrids inter-
actions. Benefits such as offering potential advantages of
synergistic, additive effects, enhanced solubility, and dis-
solution of at least one of the drug components as well as
bioavailability are associated with these solid-state materi-
als. Furthermore, MDC due to intermolecular interactions
can stabilize unstable components.[41,42]
8.1 Factors influencing MDC synthesis
It is familiar that the co-crystallization process often yields
complex hybrids other than co-crystals intended. The same
phenomenon is likely to increase when attempting to pre-
pare MDCs. Combining two drugs may result in either a
mixture or a co-crystal in a specific ratio. In cases where
a co-crystal is formed, improvements in physicochemical
properties and performance of at least one drug compo-
nent of the co-crystal system are observed. Alternatively,
in the case where another supramolecular hybrid is pro-
duced, characterization should be conducted to determine
its usefulness.[117]
Different factors are to be considered when attempting
to synthesize MDC:
∙ Like normal drug-co-former co-crystals, the success-
ful production of MDC depends on the method used.
Mechanochemistry is likely to be the best, simple and
cost-effect method to prepare MDC.
∙ A deep understanding of both components ensures a
successful co-crystal formation. The compatibility of the
MDC system components should be established. Both
drugs must possess complementary functional groups
necessary for intermolecular interactions.
∙ Many active pharmaceutical ingredients (API) with
exploitable functional groups that are readily available
for hydrogen bonding.
∙ A diversity of methods available to synthesis co-crystals
some of which will be discussed in the methodology
chapter of this thesis.
∙ Possibilities of co-crystal formation with ionic drugs.
This factor favors co-crystallization over the salt forma-
tion and,
∙ Of course, the need for that particular co-crystal on the
market motivates the search, screening and production
processes.
8.2 Synthesis of multi-drug co-crystals
Generally, MDCs are synthesized the same way as normal
single drug co-crystals and conventional methods used are
similar.[41] Some of the traditional methods for co-crystal
formation also applied to MDCs synthesis are; simple dis-
tillation, solvent evaporation, cooling crystallization, co-
grinding, and liquid assisted grinding, slurry crystalliza-
tion, melting, and sonic crystallization. The successful
application to MDCs of these methods has been justified
by a growing number of these hybrids in the literature.[41]
8.3 Advantages of multi-drug
co-crystals
MDCs offer potential advantages of synergistic benefits
in addition to enhancing solubility, dissolution as well as
bioavailability offered by normal co-crystals.Multidrug co-
crystallization as a subset of co-crystallization provides
not only the opportunity to modify the physicochemical
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properties of a drug substance but also the new strate-
gies for the development of combination therapies. MDCs,
due to the intermolecular interactions, can stabilize unsta-
ble components, [41] therefore, reducing the occurrence of
drug resistance and related side effects.
Even though the production of MDC follows the same
crystallographic procedures, there are other factors to con-
sider to successfully producing MDC. Firstly, in-depth
knowledge of both drug components of the co-crystal
is paramount to address the purpose of the product co-
crystal desired. Other factors include but not limited to
co-crystallization conditions as well as methods used. Par-
ticularly, in pharmaceutical co-crystals production, the
compatibility of two drugs, differential solubility and vari-
ations in dose must be considered.[41]
Examples of multi-drug co-crystals synthesized through
this approach include three anti-TB drugs isoniazid (INH)
and pyrazinamide (PZA) key-members of the first-line
treatment and 4-aminosalicylic acid, the second-line anti-
TB drug. Both drugs (INH and PZA) were co-crystallized
by 4-aminosalicylic acid (PAS) and two complexes have
resulted. The first complex is anhydrous formed between
INH and PAS with a 1:1 stoichiometric ratio. The second
complex was amonohydrate resulted from co-crystallizing
PYR and PAS.[119] Other reported combinations such
as molecular complexes of theophylline from its co-
crystallization with 5-fluorouracil and barbital have been
discussed in the literature.[108]
The co-crystallization of meloxicam a non-steroidal
anti-inflammatory and aspirin resulted in a co-crystal
showing a reduced time required to reach the human
therapeutic concentration compared with the parent drug,
meloxicam.[114] The co-crystal of Acetaminophen and
theophylline in a 1:1 ratio showed a better dissolution rate
than that of the physical mixture of these drugs. Other
examples include Dapsone which due to its potentials
therapeutic activity, was co-crystallized by different active
substances.[120–123]
9 CONCLUSION
With an intense demand for new medications due to
the increasing drug resistance among available medica-
tions, the desire to discover new, co-effective, and patient-
friendly compounds, force researchers to explore different
alternatives, one of them being fine-tuning the physico-
chemical properties of known APIs. Co-crystallization has
recently evolved as a better approach/route to promising
new chemical entities.
Based on a growing number of publications, co-crystals
have gained potential applications in the pharmaceutical
industry and other fields of chemistry and physics such as
agrochemistry, catalysts, food industry, energy, etc.
Not only does co-crystallization enhance the essential
properties of APIs but also plays an important role in com-
bination therapy where APIs can be combined in a single
co-crystal for multi-targets purposes. Typical examples of
these include HIV, TB, cancer treatments that require high
doses and therefore, involve the administration of many
drugs at once to achieve the necessary doses.
Even though co-crystal formation is not always suc-
cessful, the resultant multi-component adducts come with
even better properties than of the co-crystal counterpart.
Diversity of these solid-state materials that can under dif-
ferent circumstances result from co-crystallization, justify
the influence of this approach in protecting the intellectual
property of a drug.
Assisted by the CSD, crystal engineering helps the
understanding of intermolecular forces involved in hydro-
gen bonding between molecules (organic mostly). The
presence of functional groups that engage in hydrogen
bond formation makes the molecular nature of drugs
a key factor in the co-crystallization process. This fac-
tor also makes all APIs immanently prone to co-crystal
formation.[12]
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